Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9330325 | 0.85 | MAPT (0.52) | ALDH1A1CASP3MAPTCYP3A4KMT2A | |
| SCHEMBL9330335 | 0.85 | MAPT (0.52) | ALDH1A1CASP3MAPTCYP3A4KMT2A | |
| SCHEMBL16623099 | 0.85 | ALDH1A1 (0.51) | ALDH1A1CASP3CA12CA9GLS | |
| SCHEMBL6551812 | 0.84 | MAPT (0.54) | ALDH1A1CASP3MAPTMEN1CYP3A4 | |
| SCHEMBL6551817 | 0.84 | MAPT (0.54) | ALDH1A1CASP3MAPTMEN1CYP3A4 | |
| SCHEMBL3090702 | 0.84 | MAPT (0.54) | ALDH1A1CASP3MAPTMEN1CYP3A4 | |
| SCHEMBL9330371 | 0.84 | MAPT (0.54) | ALDH1A1CASP3MAPTMEN1CYP3A4 | |
| SCHEMBL21744525 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CASP3CA12CA9GLS | |
| SCHEMBL11204944 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CASP3CA12CA9GLS | |
| SCHEMBL1973155 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CASP3CA12CA9GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| CN-104603113-B | Novel 2, 3-dihydro-1H-imidazo {1,2-a } pyrimidin-5-one and 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives comprising substituted morpholines, preparation thereof and pharmaceutical use thereof | 赛诺菲 | 2020-01-21 | — | — | CN | disclosed |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2019-09-26 | — | — | US | disclosed |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | SANOFI (FR) | 2019-09-26 | — | — | US | disclosed |
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2019-04-09 | — | — | US | disclosed |
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | SANOFI (FR) | 2019-04-09 | — | — | US | disclosed |
| US-9802965-B2 | Process for the trans-selective hydroboration of internal alkynes | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20160244466-A1 | PROCESS FOR THE TRANS-SELECTIVE HYDROBORATION OF INTERNAL ALKYNES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-5656254-A | Polyaza heteroatom-bearing ligands and metal complexes thereof for imaging or radiotherapy | BRACCO INTERNATIONAL B.V. | 1997-08-12 | — | — | US | disclosed |
| US-5627286-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-05-06 | — | — | US | disclosed |
| US-5608110-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-03-04 | — | — | US | disclosed |
| EP-0629617-A1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO International B.V. (NL) | 1994-12-21 | — | — | EP | disclosed |
| EP-0380669-B1 | ISOPRENOID DERIVATIVES AND PHARMACEUTICAL PREPARATION CONTAINING SAME | TERUMO CORP (JP) | 1994-03-23 | — | — | EP | disclosed |
| US-5130483-A | Antiulcer agents and enzyme inhibitors | TERUMO KABUSHIKI KAISHA (JP) | 1992-07-14 | — | — | US | disclosed |
| US-4977170-A | Isoprenoidamine compounds which are useful antiulcer agents | SHIONOGI & CO., LTD. (JP) | 1990-12-11 | — | — | US | disclosed |
| EP-0380669-A1 | ISOPRENOID DERIVATIVES AND PHARMACEUTICAL PREPARATION CONTAINING SAME | TERUMO KABUSHIKI KAISHA (JP) | 1990-08-08 | — | — | EP | disclosed |
| US-4900749-A | Isoprenoidamine compounds useful as antiulcer agents | SHIONOGI & CO., LTD. (JP) | 1990-02-13 | — | — | US | disclosed |
| EP-0194901-A2 | Isoprenoidamine derivatives, compositions containing them, their preparation, and their use | SHIONOGI & CO., LTD. (JP) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253043-B2 | 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | MTX1, RDX, MTX2 | ALDH1A1 774/4885CASP3 1829/4885CA12 2814/4885 |
| US-11739100-B2 | 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof | CBR3, MTX1, CBR1 | ALDH1A1 1241/4885CASP3 1304/4885CA12 2437/4885 |
| US-20160244466-A1 | PROCESS FOR THE TRANS-SELECTIVE HYDROBORATION OF INTERNAL ALKYNES | HEXB, SLC9B2, CXCR4 | ALDH1A1 2738/4885CASP3 4129/4885CA12 159/4885 |
| US-20190292205-A1 | Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof | CCNY, CBR3, CBR1 | ALDH1A1 1226/4885CASP3 903/4885CA12 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.